SCHEMBL6323334

SCHEMBL6323334

CCCCCCCCNC(=O)c1c(-c2ccc(OC)nc2)noc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.44
CD274 Q9NZQ7 1/20 0.43
GABRA1 P14867 3/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 1/20 0.42
HDAC6 Q9UBN7 4/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC3 O15379 2/20 0.40
NCOR2 Q9Y618 2/20 0.40
MEN1 O00255 1/20 0.40
PABPC1 P11940 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
GABRA5 P31644 2/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316456 1.00 GAA (0.44) GAACD274GABRA1RAB9AKMT2A
SCHEMBL6319295 1.00 GAA (0.44) GAACD274GABRA1RAB9AKMT2A
SCHEMBL6323798 0.99 GAA (0.45) GAACD274GABRA1RAB9AKMT2A
SCHEMBL6315289 0.96 RAB9A (0.46) GAACD274GABRA1RAB9AKMT2A
SCHEMBL6324357 0.91 RAB9A (0.42) GAACD274GABRA1RAB9AKMT2A
SCHEMBL6317728 0.87 CD274 (0.42) GAACD274GABRA1RAB9ALMNA
SCHEMBL6324304 0.87 L3MBTL1 (0.53) GAAKMT2AHPGDHDAC6HDAC1
SCHEMBL6317605 0.85 L3MBTL1 (0.57) GAAKMT2AHPGDMEN1GABRA5
SCHEMBL6316178 0.85 GABRA1 (0.47) GAACD274GABRA1RAB9ANPC1
SCHEMBL6316368 0.85 GABRA1 (0.46) GAAGABRA1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 GAA 789/4885CD274 1439/4885GABRA1 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.